NGNE logo

NGNE
Neurogene Inc

386
Mkt Cap
$322.23M
Volume
100,321.00
52W High
$37.27
52W Low
$6.88
PE Ratio
-4.35
NGNE Fundamentals
Price
$20.47
Prev Close
$20.69
Open
$20.69
50D MA
$19.77
Beta
1.53
Avg. Volume
179,008.34
EPS (Annual)
-$4.24
P/B
1.20
Rev/Employee
$0.00
$180.20
Loading...
Loading...
News
all
press releases
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group reduced their price target on shares of Neurogene from $200.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm...
MarketBeat·3d ago
News Placeholder
Equities Analysts Set Expectations for Neurogene Q1 Earnings
Neurogene Inc. (NASDAQ:NGNE - Free Report) - Analysts at HC Wainwright raised their Q1 2026 earnings estimates for Neurogene in a report released on Thursday, March 26th. HC Wainwright analyst M...
MarketBeat·8d ago
News Placeholder
Brokers Issue Forecasts for Neurogene FY2027 Earnings
Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.9...
MarketBeat·11d ago
News Placeholder
Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital
Neurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at Lifesci Capital lowered their Q1 2026 earnings per share estimates for Neurogene in a note issued to investors on Tuesday, March...
MarketBeat·12d ago
News Placeholder
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Neurogene (NASDAQ:NGNE - Get Free Report) issued its earnings results on Tuesday. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of...
MarketBeat·13d ago
News Placeholder
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year...
Business Wire·14d ago
News Placeholder
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene (NASDAQ:NGNE) CEO and founder Rachel McMinn outlined the company's progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lea...
MarketBeat·17d ago
News Placeholder
Neurogene (NASDAQ:NGNE) CFO Sells $84,176.45 in Stock
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81...
MarketBeat·20d ago
News Placeholder
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 4,045 shares of Neurogene stock in a transaction dated Friday, March 13th. The stock was sold at an average price of...
MarketBeat·20d ago
<
1
2
...
>

Latest NGNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.